KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Research & Development (2016 - 2025)

Acadia Pharmaceuticals has reported Research & Development over the past 16 years, most recently at $84.8 million for Q4 2025.

  • Quarterly results put Research & Development at $84.8 million for Q4 2025, down 15.86% from a year ago — trailing twelve months through Dec 2025 was $328.8 million (up 8.43% YoY), and the annual figure for FY2025 was $328.8 million, up 8.43%.
  • Research & Development for Q4 2025 was $84.8 million at Acadia Pharmaceuticals, down from $87.8 million in the prior quarter.
  • Over the last five years, Research & Development for ACAD hit a ceiling of $157.0 million in Q3 2023 and a floor of $56.9 million in Q2 2021.
  • Median Research & Development over the past 5 years was $75.7 million (2022), compared with a mean of $79.2 million.
  • Biggest five-year swings in Research & Development: surged 126.17% in 2022 and later crashed 57.57% in 2024.
  • Acadia Pharmaceuticals' Research & Development stood at $66.9 million in 2021, then rose by 13.14% to $75.7 million in 2022, then dropped by 11.88% to $66.7 million in 2023, then surged by 50.93% to $100.7 million in 2024, then decreased by 15.86% to $84.8 million in 2025.
  • The last three reported values for Research & Development were $84.8 million (Q4 2025), $87.8 million (Q3 2025), and $78.0 million (Q2 2025) per Business Quant data.